Beth Fand Incollingo | Authors


Sotorasib Shows Early Activity in Advanced Non–Small Cell Lung Cancer

September 21, 2020

In patients with non–small cell lung cancer harboring a KRAS G12C mutation, an aberration without any FDA approved treatment options, a study showed that the investigation agent, sotorasib achieved encouraging antitumor activity.

Improved Responses Achieved for R/R Multiple Myeloma With Selinexor Combo

May 29, 2020

Selinexor in combination with bortezomib and dexamethasone resulted in improvements in responses and outcomes compared with bortezomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma, according to findings from the phase 3 BOSTON trial from the 2020 ASCO Virtual Scientific Program.

Utilizing Circulating Tumor DNA as a Predictor of Treatment Response in MCL

December 18, 2018

Measuring circulating tumor DNA in the blood of patients with advanced MCL may be a viable way to predict how well they will respond to specific therapies, according to study findings reported at the 2018 ASH Annual Meeting.